X-Feed Billboard (International)

The newsboard processes news from the NASDAQ Nordic portfolio company GlobeNewswire, which provides investors with company-relevant information. This relates in particular to events that may be relevant to the listing of companies or tradable financial instruments.

GlobNewswire (formerly PrimeNewswire) specializes in public relations solutions and digital media services. This feed adds another important source of information for investors to the popular X-Billboard portfolio.

System-State: Number of processed items 26.546 Notifications successully processed since Inception
GlobeNewsWire ist eine wichtige Nachrichtenquelle, die über das X-Billboard abgerufen werden kann. Sie ist Teil des Newswire-Hub, der für Börsianer wichtige internationalen Nachrichtenquellen an einem zentralen Ort bündelt. Wer sich schnell einen Überblick verschaffen will, kann sich bequem durch die Headlines scrollen. Wer sich detailliert mit den Nachrichten auseinandersetzen möchte, kann über die Detailansichten der Info-Cards direkt auf die jeweilige Nachricht und weitere Analysewerkzeuge zugreifen.
NEWS
EXPLORER
FR0000120578
State: 20.09.2024 | 9PM
Do you already know our new terminal view? Click here.
FIGI: BBG000BWBBP2
SAN

Sanofi SA
GICS: 35202010 · Sector: - · Sub-Sector: -
NAME
Sanofi SA
ISIN
FR0000120578
TICKER
SAN
MIC
XPAR
REUTERS
SASY.PA
BLOOMBERG
SAN FP
Fri, 20.09.2024       Sanofi SA

Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old

Fri, 20.09.2024       Sanofi SA

Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 study

Mon, 16.09.2024       Sanofi SA

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority)

Thu, 12.09.2024       Sanofi SA

Accord de licence entre Sanofi, RadioMedix et Orano Med pour le développement d’une nouvelle génération de radiothérapies internes vectorisées contre les cancers rares

Thu, 12.09.2024       Sanofi SA

Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers

Wed, 11.09.2024       Sanofi SA

Wed, 11.09.2024       Sanofi SA

Tue, 10.09.2024       Sanofi SA

Mon, 02.09.2024       Sanofi SA

Fri, 09.08.2024       Sanofi SA

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority)

Thu, 08.08.2024       Sanofi SA

Sarclisa induction treatment demonstrated significantly improved progression-free survival in patients with newly diagnosed multiple myeloma eligible for transplant

Thu, 25.07.2024       Sanofi SA

Online availability of Sanofi’s half-year financial report for 2024

Mon, 22.07.2024       Sanofi SA

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority)

Wed, 17.07.2024       Sanofi SA

Wed, 03.07.2024       Sanofi SA

Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD

Wed, 26.06.2024       Sanofi SA

Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM

Tue, 25.06.2024       Sanofi SA

Availability of the Q2 2024 Aide-mémoire

Fri, 21.06.2024       Sanofi SA

Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s Executive Committee

Fri, 21.06.2024       Sanofi SA

ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiran

Wed, 12.06.2024       Sanofi SA

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority)

The information provided here is not subject to any editorial processing. It is prepared fully automatically and enriched with additional information and further research options. The aim of the content is to provide information seekers with the relevant information quickly and easily. A link back to the information provider and owner ensures that the data prepared here can be compared with the source information if required. The newsboard does not show information in real time. Please contact the exchange operator for this information if required. There is no claim to completeness. High availability cannot be guaranteed. If you notice any errors in the functionality, please let us know using the "Report a Bug" form below.

RAW DATA PROCESSING means that raw data is processed without changing the content. The data is supplemented to improve the interpretation of the information in terms of usability.

Note: The newswire cross-link panel at the top allows you to quickly and easily access additional sources of information. In the terminal view, the news is filtered at company level and enables targeted searches.


On behalf of the trading community, we would like to thank the operators of the trading venues for providing information services.